Compare MPX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPX | PEPG |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 317.6M |
| IPO Year | N/A | 2022 |
| Metric | MPX | PEPG |
|---|---|---|
| Price | $8.57 | $5.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 19.3K | ★ 855.5K |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $227,666,000.00 | N/A |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | $21.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.49 | $0.88 |
| 52 Week High | $10.00 | $6.72 |
| Indicator | MPX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 57.83 |
| Support Level | $8.06 | $5.03 |
| Resistance Level | $8.75 | $6.72 |
| Average True Range (ATR) | 0.29 | 0.56 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 81.18 | 48.52 |
Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. It operates in the powerboat manufacturing business segment in Nashville, Valdosta, and Georgia. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.